Teva Collaborates With Klinge, Formycon For Semi-exclusive Commercialization Of FYB203
(RTTNews) - Teva Pharmaceuticals International, a unit of Teva Pharmaceutical Industries (TEVA), has entered into a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of FYB203, Formycon's biosimilar candidate to Eylea in Europe, excluding Italy, and in Israel. Klinge has in-licensed the global commercialization rights to FYB203 from Formycon.
Teva will lead the commercialization of FYB203 in the designated regions, to be marketed under the brand name AHZANTIVE3. Klinge will receive milestone payments and a portion from the products revenue.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.